Inhaled measles vaccine developed

Researchers have developed a new live attenuated vaccine for measles that can be inhaled.

Scientists from the Johns Hopkins Bloomberg School of Public Health and the University of Colorado have been working on and successfully tested the dry powder that is thought to have potential to contribute to a high level of sustained measles vaccination coverage, according to

Current measles vaccinations require two injections in order to provide full immunity. One is given at nine to 12 months of age and another later in childhood.

Special training is also needed to administer the current vaccine, which needs refrigeration in the field after it is reconstituted from a powdered form, reports. This preparation makes it difficult to use the measles vaccine in the developing world, where vaccine coverage remains limited.

According to the new study, published in the January 31 edition of the journal PNAS, the dry powder vaccine provided a group of macaques protection from measles in a single aerosol dose using one of two inhalers, the PuffHaler or the BD Solovent. No adverse side effects were seen.

“An effective dry powder vaccine would be tremendously helpful in less developed regions where resources are limited,” Diane E. Griffin, senior author of the study from the Bloomberg School of Public Health, said, reports. “This vaccine can be shipped as powder and does not require reconstitution or special training to administer, which could greatly increase the ease and safety of measles vaccination worldwide.”

Human trials for the powder vaccine are being developed in India.